Expanding knowledge, advancing understanding and applying scientific discoveries to enhance the health and lives of patients with diabetes is a hallmark of the Kovler Diabetes Center.
Building on a long history of seminal diabetes-related research at the University of Chicago, our affiliated principal investigators today work in a number of disciplines with implications for diabetes.
Researchers at Kovler and the University of Chicago enjoy the collaborative opportunities and advantages of an onsite Diabetes Research and Training Center. Basic scientists and clinical researchers as well as those looking for unique postdoctoral training will find unparalleled opportunities to pursue research at Kovler and the University of Chicago.
Read our recent publications:
Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes (JAMA June 8, 2021 Volume 325, Number 22)
Clinical Research Opportunities
UChicago Medicine is participating in a phase 3 clinical trial, sponsored by Dompé Farmaceutici S.p.A. This study will assess the effectiveness of the oral medication ladarixin in preserving b-cell function and delaying the progression of type one diabetes in adolescent and adult patients.
Contact Shanna Banogon, RN or visit https://clinicaltrials.gov/ct2/show/NCT04628481 for more information.
This study, Using Technology to Address Disparities and Promote Healthcare Equity in Type 1 Diabetes or EquiT1D, aims to address disparities in type 1 diabetes by providing clinical glucose monitors (CGMs) to adult patients with type 1 diabetes who have been hospitalized with diabetic ketoacidosis more than once in the last five years. A patient navigator will then help the patient learn to use their CGM.
The EquiT1D research team led by Celeste Thomas, MD, MS, will evaluate this intervention’s impact on participants’ diabetes measurements and self-management practices. Its finding could create a new standard of care for diabetes management.
Contact Elizabeth Murphy, MS, RDN, LDN for more information.
The University of Chicago is participating in the FOCUS study, sponsored by Novo-Nordisk. FOCUS is a 5-year long diabetic retinopathy outcomes trial. The goal is to establish the long-term effects of improved glycemic control when treated with once-weekly semaglutide on the development and progression of diabetic retinopathy in people with type 2 diabetes. The Principal Investigator for the study is center director Louis Philipson, MD, PhD, with Dimitra Skondra, MD, PhD serving as the Principal Ophthalmologist.
Contact Triniece Pearson, PhD, MBA, RN, CCRC for more information.
The Multicenter Assessment of the Pancreas in Type 1 Diabetes (MAP-T1D) is an international team of researchers that focus on using magnetic resonance imaging (MRI) to investigate changes in pancreas volume and microarchitecture in individuals with diabetes. Center director, Louis Philipson, MD, PhD, and Siri Atma Greeley, MD, PhD, are the principal investigators at UChicago Medicine for the MAP-T1D project.
Contact Demetra Reyes or visit https://www.map-t1d.com/ for more information.
The Kovler Diabetes Center is collaborating on My Diabetes, My Community (MDMC), an NIH sponsored research trial led by Elbert Huang, MD, and Stacy Tessler Lindau, MD, MA, that provides resources aimed at helping older patients throughout Chicagoland achieve their diabetes management goals.
Contact Sharon Velkovich, BSN, RN for more information or visit http://voices.uchicago.edu/mdmc.
The Rare and Atypical DIAbetes NeTwork (RADIANT) trial, for which center director Louis Philipson, MD, PhD, and Siri Atma Greeley, MD, PhD, are the principal investigators, is discovering and defining rare and atypical forms of diabetes—a signature project of the Kovler Diabetes Center.
RADIANT is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). RADIANT is a network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Our team of academic institutions and scientists collaborate with physicians and healthcare groups to identify people with atypical diabetes and learn more about their health.
Contact Colleen Bender, BSN, RN or visit https://www.atypicaldiabetesnetwork.org/ for more information.
TrialNet is an international network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams at the forefront of type 1 diabetes (T1D) research. They offer risk screening for relatives of people with T1D and innovative clinical studies testing ways to slow down and prevent disease progression. Screening is offered at no cost to relatives of people diagnosed with T1D. The University of Chicago is also participating in a number of innovative clinical studies offered by TrialNet.
Contact Neha Singh, RN or visit https://www.trialnet.org/ for more information.
UChicago Medicine is participating in a new clinical research study of an investigational infusion of islets in individuals who have been diagnosed with type 1 diabetes with low blood sugar and impaired hypoglycemic awareness. In this study, islets manufactured from stem cells are infused into the liver with a goal of providing replacement cells producing insulin for cells that have been lost.
Contact: Shanna Banagon, BSN, RN or Lindsay Basto, RN MSN for more information.
Diabetes Care at UChicago Medicine
Request an Appointment
To speak to someone directly, please call 1-888-824-0200. If you have symptoms of an urgent nature, please call your doctor or go to the emergency room immediately.
* Required Field
